Ipamorelin/CJC-1295 No DAC 5mg/5mg

Description

Ipamorelin / CJC-1295 No DAC (5mg/5mg) Lyophilized Powder

Product Specifications

Pharmacological Profile and Mechanism of Action

Ipamorelin is a highly selective synthetic pentapeptide designed to mimic the endogenous action of ghrelin. It functions as a targeted agonist of the growth hormone secretagogue receptor type 1a (GHS-R1a), which is located on the somatotroph cells of the anterior pituitary [cite: source: 16, source: 49]. Unlike other first-generation GH-releasing peptides (GHRPs), in vitro and in vivo studies indicate that Ipamorelin stimulates a profound GH release without simultaneously triggering the secretion of cortisol, adrenocorticotropic hormone (ACTH), or prolactin [cite: source: 15, source: 50].

CJC-1295 No DAC, also extensively documented in the literature as Modified GRF 1-29 (Mod GRF 1-29) or tetrasubstituted GRF 1-29, is a synthetic peptide analog of the biologically active 1-29 fragment of endogenous GHRH [cite: source: 59, source: 61]. The molecule incorporates four critical amino acid substitutions: an optical isomer D-Ala2 substitution, along with Gln8, Ala15, and Leu27 [cite: source: 61, source: 65]. The substitution at position 2 prevents rapid enzymatic cleavage by dipeptidyl peptidase-4 (DPP-IV), while the others reduce oxidation and enhance receptor binding affinity [cite: source: 6, source: 60]. These modifications increase the functional half-life of the peptide to approximately 30 minutes, allowing for a discrete, sustained activation of the GHRH receptor [cite: source: 61, source: 64].

Synergistic Dual-Axis GH Secretion

The principal scientific advantage of this blend is the dual-axis synergy achieved by engaging two distinct but convergent intracellular pathways. CJC-1295 No DAC binds to the GHRH receptor, activating the cyclic AMP (cAMP) and protein kinase A (PKA) signaling cascades to stimulate GH gene transcription and exocytosis [cite: source: 56, source: 61]. Concurrently, Ipamorelin binds to the GHS-R1a receptor, activating the phospholipase C (PLC) and protein kinase C (PKC) pathways, which significantly amplifies the GH release while actively suppressing somatostatin, the body’s natural GH inhibitor [cite: source: 10, source: 56]. Clinical and experimental research has demonstrated that this GHRH-GHRP synergy produces an acute, supra-additive GH pulse that is vastly superior to the administration of either peptide alone [cite: source: 14, source: 54].

Research Applications

This 5mg/5mg combination formulation is utilized strictly for laboratory and pre-clinical research. Major applications include:

• GH Pulsatility Studies: Investigating physiological, episodic somatotroph secretory bursts and their regulation by synthetic secretagogues [cite: source: 61, source: 64].
• IGF-1 Axis Research: Tracking downstream hepatic output of Insulin-Like Growth Factor 1 (IGF-1) in response to amplified, pulsatile GH stimulation [cite: source: 44, source: 55].
• Metabolic Modulation Models: Evaluating the impact of synchronized GH pulses on lipolysis, lean muscle tissue hypertrophy, cellular repair, and collagen synthesis in animal or cellular models [cite: source: 56, source: 57].

Storage, Preparation, and Purity

The Ipamorelin / CJC-1295 No DAC blend is supplied as a highly stable lyophilized powder. The unconstituted vial should be kept out of direct light and stored at -20°C (or -80°C for long-term preservation) [cite: source: 37]. Once reconstituted with bacteriostatic water or sterile saline for experimental use, the solution must be refrigerated (2°C to 8°C) to maintain structural integrity. This product has been analytically verified by High-Performance Liquid Chromatography (HPLC) and Mass Spectrometry to guarantee a sequence purity of ≥99% [cite: source: 36, source: 37].

Regulatory Disclaimer: This compound is intended for Research Use Only (RUO). It is not approved for human consumption, veterinary applications, or clinical diagnostic/therapeutic use.

References

• [cite: source: 50] Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-61.
• [cite: source: 48] Jetté L, Léger R, Thibaudeau K, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-8.
• [cite: source: 54] Veldhuis JD, Bowers CY. Determinants of GH-releasing hormone and GH-releasing peptide synergy in men. Am J Physiol Endocrinol Metab. 2009;296(5):E1085-92.